Group
HER(2) targeting TKI
The data below refer to patients treated with HER(2) targeting TKI as the sole drug class,
excluding any concurrent use of drugs from other groups.
Individual Drugs
Select a drug to view its individual evidence base (drug + SBRT, no other concurrent systemic drugs). Drugs without available data are shown greyed out.
Neratinib
No data
Sevabertinib
No data
Tucatinib
No data
Zongertinib
No data